Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Stopped early

Conditions studied: Hematological Malignancy

In brief

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.

Key facts

Study ID

NCT04093622

Run by

Fate Therapeutics

People needed

2

Starts

2019-10-04

Expected to finish

2020-04-09

Last updated by the study team

2022-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received engineered cellular immunotherapy in a Fate Therapeutics Interventional Study

You may not qualify if…

• Not Applicable

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States
• UC San Diego — San Diego, California, United States
• University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.